Julie has over 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis and is currently the Executive Chair of the Board of Directors of Mundipharma China (a global pharmaceutical leader). She previously held the positions of Global Senior Vice President and President of Greater China for Envista Holdings Corporation. She has held numerous leadership roles at Eli Lilly and Company including Senior Director, Global New Product Planning and Payer Marketing, Pricing, Reimbursement and Access of Lilly Diabetes. Prior to Eli Lilly, she was Vice President and General Manager of Asia Pacific and Japan Operations at Panomics and Affymetrix, which was acquired by Thermo Fisher Scientific. She has also served as a Board Advisor on the Board of Directors for Mars, Incorporated (a global manufacturer of confectionery, pet food and provider of animal care services) since 2019 and joined Aptar’s Board of Directors in 2023.